A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-08-09
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 56); relationship: Y
severe
serious
assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 95); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 119); relationship: N
Data queries
No data queries.